On Feb 18, regenerative medicine company Lynch Regenerative Medicineis announced they hired Madison Dini and Chad Lindemann to lead their legal and marketing functions respectively.
Lynch Regenerative Medicine, LLC was founded in 2023 by Dr. Samuel Lynch and uses platelet-derived growth factor (PDGF)–based therapies for skincare, aesthetics, and wound care.
Related: PRP/FM Options for Under-Eye Rejuvenation
"We are thrilled to welcome Madison and Chad to the executive leadership team," said Dr. Samuel Lynch, Chief Executive Officer of LRM in a statement Wednesday. "Their deep expertise navigating the complex legal, regulatory and commercial landscape of regenerative medicine makes them an exceptional fit."
According to the company’s press release, Madison Dini will oversee all legal, compliance, and corporate governance functions, as she brings more than a decade of experience advising life sciences companies on complex compliance, regulatory, and litigation matters. Formerly, as a partner at Michelman & Robinson, LLP, she served as outside general counsel and lead trial counsel in high stakes matters with significant business and legal implications.
She is also a recognized voice in the regenerative medicine space. She’s spoken nationally on relevant legal issues, helping shape industry conversations around compliance, innovation, and patient safety.
"Prior to joining LRM, I've had the opportunity to speak and write about the evolving legal landscape surrounding regenerative medicine from an independent perspective. That work was always grounded in a commitment to risk management, legal integrity, regulatory clarity, and patient safety," stated Ms. Dini. "My decision to join LRM was a natural and organic extension of that work. After closely evaluating the company's science, compliance framework, and long-term vision, I believe strongly in its commitment to doing this the right way. I am excited to help guide the next phase of responsible innovation in this space."
Chad Lindemann will oversee the strategic development and execution of the marketing strategy for all current and future products across LRM.
Lindemann is an accomplished sales and marketing executive with 20 years of experience in the Medical Aesthetics industry. Most recently, as Vice President of Marketing at Allergan Aesthetics, he led marketing for major brands including BOTOX® Cosmetic, JUVÉDERM®, CoolSculpting®, and SkinMedica®.
"In today's digital landscape, information—and misinformation—travels at unprecedented speed. As brand leaders, we have a responsibility to ensure that accurate, science-based information about our products reaches providers and patients clearly and responsibly. I'm committed to building a marketing platform rooted in transparency, education, and integrity—so decisions are guided by evidence and context, not speculation or viral narratives," Lindemann said.
